Editorial comment from Dr Yuasa to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Editorial comment from Dr Yuasa to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma

Published:2020-10-07 Issue:6 Volume:3 Page:291-291
ISSN:2577-171X
Container-title:IJU Case Reports
language:en
Short-container-title:IJU Case Reports

Author:

Yuasa Takeshi¹^ORCID

Affiliation:

1. Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research Ariake Tokyo Japan

Funder

Smoking Research Foundation

Publisher

Wiley

Subject

Linguistics and Language,Anthropology,History,Language and Linguistics,Cultural Studies

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/iju5.12228

Reference5 articles.

1. Current approaches to the treatment of advanced or metastatic renal cell carcinoma;Tenold M;Am. Soc. Clin. Oncol. Educ. Book,2020

2. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: the Canadian Kidney Cancer information system experience;Dragomir A;Urol. Oncol.,2020

4. Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma

5. Nivolumab treatment beyond progression for metastatic renal cell carcinoma: New role of metastasectomy in the immune checkpoint inhibitor era?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP